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ABSTRACT
Introduction Acute pancreatitis (AP) is an inflammatory 
disease with no specific treatment. Mitochondrial 
injury followed by ATP depletion in both acinar and 
ductal cells is a recently discovered early event in its 
pathogenesis. Importantly, preclinical research has 
shown that intracellular ATP delivery restores the 
physiological function of the cells and protects from cell 
injury, suggesting that restoration of energy levels in the 
pancreas is therapeutically beneficial. Despite several 
high quality experimental observations in this area, no 
randomised trials have been conducted to date to address 
the requirements for energy intake in the early phase of AP.
Methods/design This is a randomised controlled two-
arm double-blind multicentre trial. Patients with AP 
will be randomly assigned to groups A (30 kcal/kg/day 
energy administration starting within 24 hours of hospital 
admission) or B (low energy administration during the first 
72 hours of hospital admission). Energy will be delivered 
by nasoenteric tube feeding with additional intravenous 
glucose supplementation or total parenteral nutrition if 
necessary. A combination of multiorgan failure for more 
than 48 hours and mortality is defined as the primary 
endpoint, whereas several secondary endpoints such as 
length of hospitalisation or pain will be determined to 
elucidate more detailed differences between the groups. 
The general feasibility, safety and quality checks required 
for high quality evidence will be adhered to.
Ethics and dissemination The study has been approved 
by the relevant organisation, the Scientific and Research 
Ethics Committee of the Hungarian Medical Research 
Council (55961-2/2016/EKU). This study will provide 
evidence as to whether early high energy nutritional 
support is beneficial in the clinical management of AP. The 
results of this trial will be published in an open access way 
and disseminated among medical doctors.
Trial registration The trial has been registered at the 
ISRCTN (ISRTCN 63827758).
BACkgRound
Acute pancreatitis (AP) is an inflammatory 
disease of the exocrine pancreas which is life 
threatening in its severe form. Unfortunately, 
while the overall mortality of AP is around 
2–5%, and in its severe form 25–57%, no 
specific treatment is available. Besides the 
limited interest of pharmacological compa-
nies, the main reasons are (1) the small 
number of research teams in the field and 
(2) the lack of collaboration between basic 
and clinical scientists. Importantly, many new 
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Protocol
Strengths and limitations of this study
 ► Strength 1: This is a randomised controlled two-arm 
double-blind multicentre trial which provides the 
first type A evidence concerning the necessity of 
early energy intake for patients with AP.
 ► Strength 2: The study enjoys continuous support 
from an International Translational Advisory Board 
(ITAB) including several well established experts.
 ► Strength 3: Data will be separately handled by an 
Independent Data Management Board (IDMB).
 ► Strength 4: There are no unknown drugs/therapy 
used in the study, therefore no adverse and serious 
adverse events are expected.
 ► Limitation 1: In order to detect a treatment effect of 
at least 50% of the early treatment, a sample size of 
957 subjects will be necessary to be recruited which 
will delay the final conclusion of the study.
 ► Limitation 2: The double-blind arrangement of the 
study requires many staff members working on 
the project which may limit the number of joining 
centres.
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therapeutic targets were identified in the last decade with 
clear translational merits.1–8 One of the main highlights 
among them is the discovery of energy depletion in the 
early phase of AP.1 3–5 7–17
It has been shown that, almost independently of the 
aetiological factors, the early phase of AP is almost the 
same. Bile acids, ethanol, fatty acids and the latter’s 
metabolite fatty acid ethyl esters cause mitochondrial 
damage and ATP depletion in pancreatic ductal and 
acinar cells, driving the cells to death and causing pancre-
atic necrosis.1 3 4 10–14 18–31 Very importantly, restoration of 
ATP levels in both cell types prevented cell death and at 
least partially restored their function.1 9 In experimental 
pancreatitis models the same observations have been 
revealed.10–21 Although these experimental observations 
clearly suggest that restoration of the energy level could 
be a therapeutic tool in AP, this has not been translated 
into clinical trials.
One of the best and most physiological way of deliv-
ering energy to a patient is enteral nutrition (EN). Not 
surprisingly, besides fluid resuscitation this is almost 
the only way to significantly reduce mortality in AP.22–33 
Recent analyses of prospectively collected data from 600 
patients with AP showed that the mortality is 27% with 
EN and 57% without EN in the severe form (SAP).34 
Importantly, EN decreases mortality but also reduces the 
frequency of multiorgan failure and the need for inter-
ventions in patients with SAP.35 No data are available on 
whether early or on-demand nutrition/energy supply is 
beneficial in SAP. The recently published Dutch PYTHON 
study suggests that there is no difference between early 
and on-demand enteral tube feeding in SAP, but patients 
may have received an insufficient amount of energy at 
the early phase of the disease.36 37 In the early EN group, 
patients received over 20 kcal/kg/day only from day 3 
onwards whereas, in the on-demand group, they received 
energy supplementation only from day 6.37 In mild and 
moderate AP (MAP) much less information is available 
concerning the usefulness of EN. There is a large variety 
of protocols on EN in MAP. Immediate oral feeding,38 
nasojejunal feeding39–41 and nasogastric feeding42 43 have 
all been used. Notably, immediate oral feeding signifi-
cantly decreased the length of hospital stay.38 Early 
(within 24 hours) nasogastric EN was well tolerated and 
reduced the intensity and duration of abdominal pain, 
decreased the necessity for opiates and almost completely 
eliminated the risk of oral food intolerance.42 In order 
to obtain stronger evidence of the usefulness of early EN 
in MAP and SAP, we performed a systematic review and 
meta-analysis which showed that early EN can be benefi-
cial in both MAP and SAP.35 However, we also realised the 
lack of multicentre randomised control trials addressing 
energy intake in the early phase of AP.
The main objective of this trial is to determine whether 
early energy supplementation is beneficial to patients 
with AP. Our hypothesis is that early energy supplemen-
tation will prevent the cells from death or decrease the 
size of necrosis if it occurs. This will decrease the systemic 
immune response that will result in a lower frequency of 
multiorgan failure and mortality. To prove this concept, 
a randomised clinical trial involving all patients with AP 
is needed.
METhodS
Design
This is a randomised controlled two-arm double-blind 
multicentre trial. Patients with AP will be randomly 
assigned to groups A (high energy administration starting 
within 24 hours of hospital admission) and B (no energy 
administration after 24 hours of hospital admission).
Trial organisation, committees and boards
GOULASH is designed and coordinated by the Centre 
for Translational Medicine at the University of Pécs and 
the Hungarian Pancreatic Study Group (HPSG). HPSG 
was established in 2011 in order to stimulate research 
in pancreatic diseases. To date, HPSG has published the 
relevant guidelines of pancreatic diseases in order to 
improve patient care in the field of pancreatology44–47 
and has initiated four prospective clinical trials (EASY, 
PREPAST, APPLE and PINEAPPLE).48–51
The following committees and boards will be involved:
Steering committee (SC)
The Steering committee (SC) will be led by PH (gastro-
enterologist, internal medicine specialist). The members 
will be KM (medical doctor, full time employee on the 
project), ÁV (gastroenterologist, internal medicine 
specialist), ZM (intensive care specialist), TM (clin-
ical research specialist), AS (multidisciplinary unit 
specialist), MP (gastroenterologist, internal medicine 
specialist), NF (radiologist), DK (surgeon) and IB 
(interventional radiologist). SC will make decisions 
concerning all relevant questions including the drop-
outs during the study.
International translational advisory board (ITAB)
The committee will include a gastroenterologist (MML), 
a surgeon (JPN) and basic scientists (MST, OHP). ITAB 
will continuously monitor the progress of the study and 
will give advice to the SC.
The study was designed by the SC and ITAB. The 
study is financially sponsored by the University of Pécs, 
the Hungarian Academy of Sciences and the National 
Research, Development and Innovation Office. Neither 
sponsors were involved in the design of the study, and 
they will have no access to the database management or 
to the randomisation code.
Study population
All patients diagnosed with AP will be informed of the 
possibility of taking part in the GOULASH study. After the 
consent form is signed, a computer using a block rando-
misation protocol will randomise the patients (figure 1).
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Figure 1 Flow chart of participants according to the SPIRIT 2013 statement.53
Inclusion criteria
The inclusion criteria are: (1) patients over 18 years of 
age; (2) diagnosed AP on the base of the ‘2 out of 3’ 
criteria of the IAP/APA guideline52: (a) upper abdom-
inal pain; (b) serum amylase or lipase >3x upper limit of 
normal range; (c) characteristic findings on pancreatic 
imaging; however those patients without abdominal pain 
will be excluded because the onset of AP cannot be deter-
mined; (3) signed written informed consent form.
Exclusion criteria
The exclusion criteria are: (1) hospitalisation 72 hours 
before admission; (2) abdominal pain >120 hours (5 
days); (3) delirium tremens; (4) Child-Pugh C stage liver 
cirrhosis; (5) AP due to malignancy; (6) already on artifi-
cial nutrition (EN or PN); (7) pregnancy; (8) BMI >40 or 
<18; (9) age >80 years; (10) ketoacidosis; and (11) when-
ever CT with contrast is contraindicated.
Sample size
Sample size calculation was based on the Hungarian 
National Registry operated by the HPSG. Our recent 
analyses indicated that multiorgan failure existing for 
more than 48 hours arises in 9%, whereas mortality 
occurs in 2.8% of all patients with AP.34 Altogether they 
represent around 10% of all AP patients. In order to 
detect a treatment effect of at least 50% of the early treat-
ment, a sample size of 957 subjects will be necessary to 
be recruited using a 10% drop-out rate, 80% power and 
95% significance level. The calculation was performed 
by the independent data management and biostatistics 
provider company (IDMB, Adware Research Ltd, Bala-
tonfüred, Hungary).
Randomisation
In each centre participants will be divided into two groups 
receiving one of the two study treatments. The allocation 
of participants to the different groups will be carried out 
based on predefined randomisation lists created sepa-
rately for each recruiting centre. The randomisation lists 
will be prepared with a block size of 4 and with an alloca-
tion ratio of 1:1.
duration
The planned starting date of the study is 1 January 2017 
and the planned finishing date of the study is 1 January 
2020.
Blinding
The medical staff (eg, those taking the measurements 
such as blood pressure, examining health records for 
events such as abdominal pain, reviewing and interpreting 
examination results such as X-ray or CT) and the patient 
receiving the intervention will be blinded to knowledge 
of treatment assignment. The person providing the inter-
vention cannot be blinded in this study. Sealed envelopes 
ensure the allocation sequence. Nutritional support 
equipment will be covered until the fourth day to ensure 
that only the person who made the randomisation will 
know into which group the patient was enrolled.
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Figure 2 Schedule of enrolment, interventions and assessments according to the SPIRIT 2013 statement.53 Patients will be 
randomised to group A (high energy) or B (low energy). Online supplementary figure 1 Form A contains the parameters collected 
on admission. Online supplementary figure 2 Form B contains parameters collected every day during hospitalisation. Online 
supplementary figure 3 Form C contains parameters collected 1 month after hospital discharge.
Intervention
Based on the currently available guidelines, enteral 
feeding can be started at any time for patients with AP. In 
addition, no calorie restriction/order has been described. 
Therefore, both groups can be regarded as being treated 
within accepted practice recommendations.
In this study, early high energy administration will be 
the intervention. Patients will be randomised to group A 
or B (see figure 2).
Groups
In group A, high energy will be delivered after admission. 
Patients will receive a 10 Ch nasogastric (NG) or nasojejunal 
(NJ) feeding tube on admission. EN will be immediately 
started as follows: on day 0 (from admission until the start 
of EN, which can vary from 2 to 24 hours): calorie intake 
will be 0 kcal/kg/day; from day 1, high energy enteral tube 
feed 30 kcal/kg/day will be provided until the oral feeding 
starts. In group B, low energy administration will be deliv-
ered after hospital admission. Patients will receive a NG or 
NJ feeding tube at admission as described above. On day 0 
(from admission until the start of EN): calorie intake will 
be 0 kcal/kg/day; on day 1, 0 kcal/kg/day; on day 2, 10 
kcal/kg/day, on day 3, 20 kcal/kg/day and from day 4, 30 
kcal/kg/day will be delivered until the oral feeding starts. 
However, between groups A and B only the amount of calo-
ries administered will be different. Patients will receive the 
same amount of fluid and ions during EN (see below).
Ingredients of enteral tube feed: high energy enteral tube feed 
(100 mL)
Energy
150 kcal (630 kJ), protein 6 g (16%E), carbohydrate 18.3 g 
(49%E), fat 5.8 g (35%E) + minerals: 134 mg sodium, 
201 mg potassium, 108 mg calcium, 108 mg phosphorus, 
34 mg magnesium, 100 mg chloride (0%E). In this study 
we will use Nutrison Energy (Numil Ltd, Budapest, 
Hungary), which is a registered product in Hungary (reg. 
number: 1217).
Zero energy enteral tube feed (100 mL)
Energy
0 kcal (0 kJ), protein 0 g, carbohydrate: 0 g, fat 0 g + 
minerals: 134 mg sodium, 201 mg potassium, 108 mg 
calcium, 108 mg phosphorus, 34 mg magnesium, 5.562 g 
chloride (0%E). In this study the local institutional phar-
macy will provide it in accordance with the Hungarian 
regulations. Whenever 10 or 20 kcal/kg/day calories are 
to be delivered, a mixture of the abovementioned two 
solutions will be used.
group.bmj.com on December 20, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 5Márta K, et al. BMJ Open 2017;7:e015874. doi:10.1136/bmjopen-2017-015874
Open Access
Type of enteral tube
Patients neither vomiting nor having gastric fluid reten-
tion >250 mL will receive a NG tube. Patients either 
vomiting or having gastric fluid retention >250 mL will 
receive a NJ tube (placement will be done either endo-
scopically or radiologically). In case of Glasgow Coma 
Score (GCS) 14 or lower in a patient who is not intubated, 
the NG tube will be replaced by a NJ tube (risk of aspira-
tion). Abdominal X-ray will be used to check the position 
of the tube.
Start of mixed feeding (around 2620 kcal): 1000 mL 
tap water distributed for 24 hours and 300 g (around 1900 
kcal) biscuits/toasts/low fat meal (containing at least 
75% carbohydrate) orally plus enteral tube feed (480 mL, 
720 kcal/day) will be started on the day when: (1) abdom-
inal pain has ceased for at least 6 hours before the new 
day started; (2) the C-reactive protein (CRP) level has 
started decreasing; and (3) the amylase or lipase level has 
started decreasing.
Start of total feeding (around 2000 kcal): if the patient 
has no symptoms during the mixed oral/enteral feeding 
and the CRP, amylase or lipase levels are not rising again, 
total feeding (according to local policy) can be started.
Other issues
The speed of EN will be different for patients depending 
on the body weight, however, the maximum speed of 
EN cannot exceed 65 mL/hour. In case of difficulties 
reaching an intake of 30 kcal/kg/day calories (if the 
patient’s body weight is >75 kg), additional intravenous 
calories will be added using Sterofundin G. A maximum 
of 2000 mL (400 kcal) can be delivered in this way. If NG 
feeding is not tolerated, the NG tube will be replaced by a 
NJ tube as described above. If NJ feeding is not tolerated, 
EN will be reduced by 50% and increased again gradu-
ally until tolerated. If the re-increasing process is still not 
tolerated, total parenteral nutrition (TPN) will be started 
to reach the required energy target. In patients with SAP, 
TPN must be delivered via a central venous catheter.
other treatment of subjects
General treatment indicated by the IAP/APA guideline 
will be utilised.52
discharge of patients
Uniformisation of the length of hospital stay is necessary 
to avoid bias concerning length of hospital stay. Readmis-
sion within 1 week after discharge has to be considered 
as the same hospital admission. Patients will be counted 
as discharged from hospital/from the study when (1) 
oral feeding is tolerated for 24 hours; (2) amylase/lipase 
levels are not elevated after total enteral feeding; (3) CRP 
level is <50 mg/L; (4) abdominal pain has completely 
resolved; and (5) no other pancreatitis-related complica-
tion requiring hospitalisation is detected.
Endpoints
The following primary endpoints will be calculated: 
a combination of multiorgan failure for more than 
48 hours and mortality. The following secondary 
endpoints will be analysed: (1) pancreatic necrosis; (2) 
nutrition-related complications (eg, diarrhoea, aspira-
tion pneumonia, pneumothorax due to central TPN 
catheter placement); (3) need for conversion from NG 
to NJ feeding tube; (4) need for conversion from EN to 
TPN; (5) days until the start of total feeding; (6) use of 
antibiotics; (7) pain relapse; (8) CRP; (9) white blood 
cells; (10) procalcitonin; (11) infection; (12) length of 
hospital stay; (13) need for ICU admission; (14) length 
of ICU therapy; (15) organ failure; (16) complications; 
(17) costs calculation. Notably, only direct costs will be 
calculated that include all medications, services, salaries 
of healthcare professionals, equipment and day care 
costs.
Monitored parameters during hospitalisation
There will be a large variety of parameters monitored 
during the study (eg, medical history, physical examina-
tion, laboratory tests, diagnostic imaging, therapy, inter-
ventions). Form A will contain the parameters collected 
on admission (online supplementary figure 1). Form B 
will contain parameters collected every day during hospi-
talisation (online supplementary figure 2). Form C will 
contain parameters collected 1 month after hospital 
discharge (online supplementary figure 3). For details 
see supplementary materials or web page (http://www. 
pancreas. hu/ en/ studies/ goulash), which will be avail-
able from February 2017. Data collection on the case 
report form (CRF) will be done electronically (see data 
management).
data management and statistical analyses
Data handling
Data will be handled by the IDMB. Electronic CRF (eCRF) 
will be used. The Investigator will ensure that the data 
in the eCRF are accurate, complete and legible. Detailed 
data flow will be described in a Data Management Plan 
(DMP). Data from completed eCRFs will be validated 
under the direction of the Data Manager at IDMB 
according to a Data Cleaning Plan (DCP). Any missing, 
implausible or inconsistent recordings in the eCRFs will 
be referred back to the Investigator using a data query 
form (DQF), and be documented for each individual 
subject before clean file status is declared. All changes 
to eCRFs will be recorded. Before Data Base Lock the 
Data Review Meeting will decide and document necessary 
steps related to any issue in the database and define the 
analysis sets. Members of the Data Review Meeting are a 
delegated investigator, biostatistician and data manager. 
Adverse events will be coded using MedDRA (AdWare 
Research Ltd), who will act as IDMB, works according to 
GCP, GLP, FDA 21CFR PART11 and other relevant regu-
latory requirements. AdWare  Ltd. has GLP and ISO 9001 
certificates.
Study populations
Three analysis populations will be defined:
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Safety Analysis Set (SAS): all patients enrolled in the 
study.
Per Protocol Set (PPS): all enrolled patients who 
finished the study conforming to the requirements of the 
study protocol.
Intention to Treat (ITT): all randomised participants 
who start on a treatment, excluding consent withdrawals.
Withdrawal of a subject from PPS
Any participants/investigators and the IDMB can submit 
recommendations for dropouts from the PPS group with 
reasons given to the SC. All recommendations will be 
filed. The SC will discuss all the information and, if the 
alteration in the protocol would be expected to have any 
bearing on the interventions and outcomes of the study, 
the patient will not be included in the final per-protocol 
analysis. Automatic dropout from the per-protocol group 
shall be ordered if: (1) any of the exclusion criteria are 
diagnosed during the course of AP; (2) at least 50% 
of the energy requirement is not achieved on any days 
during the study; (3) parameters required for answering 
the primary endpoints are missing; or (4) serious medical 
reasons not related to pancreatitis occur (eg, accidents, 
stroke).
Applied software
Statistical analysis will be performed using SAS 9.2 or 
SPSS 19 (or later) statistical packages; Microsoft MS Word 
will be used for reporting.
Statistical methods
Baseline patient and disease characteristics will be anal-
ysed using descriptive analysis. Demographic and base-
line characteristics will be summarised for the overall 
study population. Continuous variables will be described 
by mean, median, SD and ranges and categorical vari-
ables will be described by absolute and relative frequen-
cies. A graphical presentation of efficacy variables will 
be prepared, if applicable. Descriptive statistics for both 
the primary and secondary parameters will be analysed 
similarly. Mean changes (with 95% CI) from baseline to 
end-of-study visit will also be presented. χ2tests will be 
applied to compare proportions between the different 
groups. Mortality/extended multiorgan failure will be 
investigated using the Kaplan–Meier analysis method, 
while subgroup comparisons will be performed using the 
χ2 or Fisher’s exact test, as appropriate. For safety data, 
descriptive statistics and individual listings of adverse 
events will also be presented.
Subgroups
The following subgroups will be made during statis-
tical analyses: (1) ages (<40 years, 40–59 years, 60–80 
years); (2) BMI (<20, 20–24, 25–29, 30–35, >35); (3) 
start of abdominal pain before admission (≤24 hours, 
24–48 hours, ≥48 hours); (4) severity of the disease SAP 
and MAP. In all subgroup analyses, aetiologies will be 
done descriptively. No confirmatory statistical testing will 
be applied. Hence, statistical tests and p values attached 
to them will be regarded as descriptive and not as tests of 
hypotheses.
Details of the applied statistical tests will be described in 
the Statistical Analysis Plan.
Early quality assessment
Early quality assessment check will be performed on the 
first 100 patients. The IDMB (AdWare Ltd) will perform 
an independent assessment of the trial-related docu-
ments and activities, with the aim of ensuring the respect 
of subjects' rights, safety and well-being and to guarantee 
the plausibility of the clinical data. The similarity of the 
groups at baseline will also be checked. The IDMB will 
report to the SC. The SC will discuss all the information 
and, if the differences would be expected to have any 
bearing on the interventions and outcomes of the study 
or the overall dropout rate from PPS is >20% of all partic-
ipants who were randomised or allocated into each group 
or the differential dropout rate is >15% between the 
arms, the study needs to be reassessed and the IDMB will 
make recommendations regarding either re-evaluation 
of power calculation, extension of recruitment period, 
extension of number of study centres or termination of 
trial.
Interim analyses and premature termination of the study
The IDMB can also recommend to stop the trial early 
for ethical reasons if one of the groups clearly shows 
evidence of a significant benefit. An interim analysis 
will be performed on the primary endpoint when 50% 
of patients have been randomised and discharged from 
hospital. The interim analysis will be performed by the 
IDMB, who will report to the SC.
The Haybittle–Peto boundary approach will be used. If 
the interim analysis shows a probability of ≤0.001 that a 
difference as extreme between the treatments is found, 
given that the null hypothesis is true, then the trial will be 
stopped early.
Centres
The trial will start in two centres (University of Debrecen 
and University of Pécs), after which the study is open for 
other centres. In all cases the IDMB will make an audit of 
the centre and will report to the SC. The SC has the right 
to decide whether the centre meets the required quality 
to join the study. Compulsory requirements for a centre 
are: (1) it needs to treat at least 50 patients with AP a year; 
(2) it needs to have all the equipment required for the 
study; (3) besides the regular medical team, the centre 
has to appoint at least one doctor and one nurse/admin-
istrator fully available for the trial with no additional 
commitments which can interfere with her/his duty when 
her/his availability is required; (4) the blinding described 
above can be fully utilised; (5) all persons need to attend 
a preliminary meeting where all the details concerning 
the studies are discussed fully and have qualified as inves-
tigators in a GCP course. Centres wishing to join need 
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to send a letter of intent to the corresponding author by 
email.
Publication policy
Centres providing more than 25 patients can provide 
two authors to the authorship list. Every additional 25 
patients will give the opportunity to nominate an addi-
tional author.
Feasibility
As a general protocol for the treatment of AP at the 
Centre for Translational Medicine at the University 
of Pécs, patients with AP receive early EN (using a NG 
tube). Patients receive 50 mL Nutrison Energy per hour 
starting immediately when they arrive to the ward from 
the Emergency Department. Patient data between the 
period 1 January 2016 to 31 May 2016 were analysed and 
the following observations were noted. (1) In 85% of all 
AP admissions early EN could have been started within 
24 hours; in 15% of cases it was not achievable due to 
delayed transfer to the ward or vomiting. In these cases, 
patients received a NG tube later or they received a NJ 
tube whenever X-ray assistance was available. (2) Around 
80% of NG-fed patients tolerated NG feeding without any 
complications. For the rest of the patients who had gastric 
retention or vomiting, NG feeding was stopped and they 
received a NJ tube whenever X-ray assistance was available. 
(3) Comparing the outcome (rate of severity, mortality, 
necrosis, intervention, etc) of this treatment protocol 
with the nil per os protocol used in most Hungarian 
hospitals showed that patients enjoyed benefits with no 
risk of early enteral feeding, which data confirm the liter-
ature described in the introduction. About 250 patients 
at the University of Pécs and about 150 patients at the 
University of Debrecen are admitted annually. Therefore, 
if no other institution joins the study, it can be completed 
within 3 years.
Safety
Since no unknown drugs/therapy are used in the study, 
no adverse or serious adverse events are expected/inter-
pretable that would be attributable to the intervention 
during the trial. In this trial the IDMB will examine safety 
variables after every 16 patients have completed. More-
over, investigators will report adverse or serious adverse 
events on a separate form which has to be sent to the 
IDMB and SC. The SC will discuss and, if the adverse 
effect is confirmed, it will be reported to the relevant 
institutional and national ethical committee (http://
www. ett. hu/ tukeb. htm).
Additional information and future plan
Blood samples (serum and plasma) from all patients will 
be stored in order to study laboratory parameters later if 
required (eg, the laboratory could not measure it), and 
in order to build up a biobank for later clinical studies 
to which all participants will be given informed consent. 
The samples will be stored at −80°C. A follow-up study 
(called GOULASH PLUS) is under preparation in order 
to follow the patients for up to 5 years after the study. The 
study protocol will also be published.
dISCuSSIon
Here we report the protocol of a prospective double-blind 
randomised controlled trial to study the effects of early 
energy restoration in AP. The preclinical studies1 9 and 
meta-analyses suggest that early energy supplementation 
should be beneficial. Our main hypothesis is that elevating 
the energy level of acinar and ductal cells will prevent 
these cells from injury, therefore decreasing the extent 
of necrosis during AP. Since both the local and systemic 
complications (immune response) largely depend on the 
extent of the necrosis, we propose that this intervention 
will reduce multiorgan failure and mortality in AP as well. 
Although nutritional interventions for patients with mild 
pancreatitis are probably not needed, we must involve 
all patients with AP in the study. It has to be highlighted 
that the main aim of the study is not to find new treat-
ments for MAP or SAP but to prevent the development of 
SAP. This is the reason why severity cannot be a selection 
criterion but has to be the primary endpoint. Concerning 
ethical issues, this study has very low risk for patients. The 
enteral solution (Nutrison Energy) used in this study is 
widely used in several diseases related to malnutrition in 
patients and has almost no contraindications, therefore 
no adverse events are expected during the trial.
EThICS And dISSEMInATIon
The trial is registered at the ISRCTN registry 
(ISRCTN63827758) and received relevant ethical 
approval with the reference number 55961-2/2016/EKU 
issued by the Scientific and Research Ethics Committee of 
the Medical Research Council. At the end of the project 
we will disseminate our results to the medical community 
and will publish our results via open access.
ConCLuSIon
This study provides the first type A evidence concerning 
the necessity of energy intake for patients with AP. This 
protocol is the first version of the trial completed on 24 
May 2017.
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